Abstract Titles
Skip to Late-Breaking Abstracts »
All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Onsite Posters
Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.
ePosters
ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 694 | Poster Presentation | Possible immune-modulation of CDK4/6 inhibitors and clinical trial development in betel-nuts related head and neck squamous cell carcinoma in Taiwan | Jo-Pai Chen, MD; Jui-Ying Chang; Hsiang-Fong Kao, MD; Ruey-Long Hong, MD, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Clinical study;Solid tumors |
| 695 | Poster Presentation | Combination of click chemistry-based SQ3370 with immunotherapies enhances antitumor effect in murine tumors with minimized systemic toxicity | Amir Mahmoodi, MS; Sangeetha Srinivasan, PhD; Michael Zakharian, MS; Nathan A. Yee, PhD; Jesse M. McFarland, PhD; Jose M. Mejia Oneto, MD, PhD | Immune-stimulants and immune modulators | Antigen presenting cells;Dendritic cell;Inflammation;Monocyte/Macrophage;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 696 | Poster Presentation | Single-cell RNA-seq reveals the critical roles of the STING- and MDA5-mediated cytosolic nucleic acid-sensing pathways as well as IFNAR/STAT2 signaling in recombinant MVA-induced antitumor immunity | Shuaitong Liu, MS; Gregory Mazo; Tuo Zhang; Ning Yang; Yi Wang; Adrian Tan; Jiahu Wang; John Choi; Jenny Zhaoying Xiang; Taha Merghoub, PhD; Jedd D. Wolchok, MD/PhD; Liang Deng, MD, PhD | Immune-stimulants and immune modulators | Chemokine;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 697 | Poster Presentation | Telomerase-Driven Telomeric DNA Modification in Cancer Cells Leads to Efficient Induction of cGAS-mediated Innate and Adoptive Immune Responses | Mihail Obrocea, MD; Jerry Shay, PhD; Sergei Gryaznov, PhD; Ilgen Mender; Silvia Siteni; Vlad Vitoc | Immune-stimulants and immune modulators | Checkpoint blockade;Costimulation;T cell;Targeted therapy |
| 698 | Poster Presentation | PD-L1 targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors | Veronica G. Zeng, Ph. D.; Gregory L. Moore, PhD; Juan E. Diaz, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Ruschelle Love; Matthew Dragovich, PhD; Rumana Rashid, PhD; Irene Leung, PhD; Michael J. Hackett, PhD, DABT; Jing Qi, PhD; Charles G. Bakhit, BS; Umesh Muchhal, PhD; Norman J. Barlow, PhD, DVM, MBA; John R. Desjarlais, PhD; Michael Hedvat, PhD | Immune-stimulants and immune modulators | Bispecifics;Checkpoint blockade;Costimulation;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 699 | Poster Presentation | ATYR2810 an anti-NRP2 monoclonal antibody targets tumor-associated macrophages | Samantha K. Tyler, BSc; Michaela Ferrer; Erik Escobedo, BS; Kaitlyn Rauch, BS; Sofia Klopp-Savino; Justin Rahman, BS; Zhiwen Xu, PhD; Esther Chong, PhD; Suzanne Paz, PhD; Leslie Nangle, PhD | Immune-stimulants and immune modulators | Antibody;Gene expression;Immune suppression;Monocyte/Macrophage;Myeloid cells;T cell;Tumor microenvironment |
| 700 | Oral Presentation | Increasing MHC-I expression to potentiate immune checkpoint blockade therapy | Shengqing Gu, PhD; Wubing Zhang; Xiaoqing Wang; Peng Jiang; Nicole Traugh; Ziyi Li; Clifford Meyer; Blair Stewig; Yingtian Xie; Xia Bu; Michael P. Manos; Alba Font-Tello; Evisa Gjini, PhD; Ana Lako; Klothilda Lim; Jake Conway; Alok K. Tewari; Zexian Zeng; Avinash Das Sahu; Collin Tokheim; Jason L. Weirather, PhD; Jingxin Fu; Yi Zhang; Benjamin Kroger; Jin Hua Liang; Paloma Cejas; Gordon J. Freeman, PhD; Scott J. Rodig, MD, PhD; Henry W. Long; Benjamin E. Gewurz; F. Stephen Hodi, Jr., MD; Myles Brown; X Shirley Liu, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Gene expression |
| 701 | Poster Presentation | Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: Clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC) | Jason J. Luke; Jaime R. Merchan, MD; Brett GM. Hughes, MD; Jeffrey A. Sosman, MD; Abhishek Tripathi, MD; Igor Puzanov, MD, MSCI; Thomas U. Marron, MD, PhD; Kristen A. Marrone, MD; Craig M. Hill, PhD; James Janc, PhD; Jenny Rudnick, BS, PhD; Shenshen Hu, PhD; Mehrdad Mobasher, MD, MPH; Suresh Mahabhashyam, MD, MPH; Richard A. Miller, MD | Immune-stimulants and immune modulators | Antibody;B cell;Clinical study;Clinical trial;COVID and Immunotherapy;Tumor antigens |
| 702 | Poster Presentation | TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies | Wenqing Jiang, PhD; Zhengyi Wang, PhD; Zhen Sheng, PhD; Jaeho Jung, PhD; Taylor B. Guo, PhD | Immune-stimulants and immune modulators | Antibody;Bispecifics;Costimulation;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 703 | Poster Presentation | Favorable pre-clinical safety profile of the novel not-alpha IL-2 agonist ANV419 supports first in human clinical development | Christoph Huber, PhD; Guzman Alonso; Elena Gerralda; Christoph Bucher; Philippe Jacqmin; Andreas Katopodis, PhD; Jennifer Sims | Immune-stimulants and immune modulators | Antibody;Costimulation;Cytokine;Immune adjuvant;NK/NKT cell;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs) |
| 704 | Poster Presentation | The computationally designed human antibody, AU-007, mediates human immune activation by endogenous IL-2, while uniquely breaking the IL-2 auto-inhibitory loop and preventing Treg expansion | Inbar Amit, Ph.D.; Itay Levin, Ph.D.; Timothy Wyant, Ph.D.; Natali Levitan, M.Sc.; Reut Barak, Ph.D; May Ben-Mayor, M.Sc.; Olga Bluvshtein, M.Sc.; Noam Grossman, M.Sc.; Yehezkel Sasson, Ph.D.; Guy Nimrod, Ph.D.; Michael Zehnin,, Ph.D.; Sharon Fischman, Ph.D.; Marek Štrajbl, Ph.D.; Liron Danielpur, M.Sc.; Aron Knickerbocker, B.Sc., M.B.A.; James Vasselli, M.D.; Yanay Ofran, Ph.D. | Immune-stimulants and immune modulators | Antibody;NK/NKT cell;Regulatory T cell (Treg cell);T cell |
| 706 | Poster Presentation | Conditional Cytokine Therapeutics for Tumor-Selective Biological Activity: Preclinical characterization of a dual-masked IFN-a2b | Alexey Berezhnoy, PhD, DVM; Hsin Wang; Na Cai; Hikmat Assi, PhD; Nicole Lapuyade; Madan Paidhungat; Kenneth R. Wong, MA; Michael Krimm; Robert Dunn, PhD; Dylan L. Daniel, PhD; Marcia Belvin, PhD; Erwan Le Scolan, PhD | Immune-stimulants and immune modulators | Antibody;Checkpoint blockade;Cytokine;Immune contexture;Immune suppression;Immune toxicity;Inflammation;Tumor infiltrating lymphocytes (TILs);Tumor stroma |
| 707 | Poster Presentation | IL12 Fc-fusions engineered for reduced potency and extended half-life exhibit strong anti-tumor activity and improved therapeutic index compared to wild-type IL12 agents | Matthew J. Bernett, PhD; Ke Liu, PhD; Christine Bonzon, PhD; Michael J. Hackett, PhD, DABT; Katrina Bykova, PhD; Rumana Rashid, PhD; Nicole Rodriguez, PhD; Nargess Hassanzadeh-Kiabi, PhD; Connie Ardila; Norman J. Barlow, PhD, DVM, MBA; Irene Leung, PhD; Hanh Nguyen; Araz Eivazi; Kendra N. Avery, PhD; Rajat Varma, PhD; Umesh Muchhal, PhD; John R. Desjarlais, PhD | Immune-stimulants and immune modulators | Antibody;Bispecifics;Cytokine;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment |
| 708 | Poster Presentation | Novel ways to exploit IL-21 to augment adoptive T cell transfer therapy against tumors | Anna C. Cole, BA; Guillermo O. Rangel RIvera, B.S.; Aubrey S. Smith, BS; Megan M. Wyatt, MS; Brandon Ware, PhD; Hannah M. Knochelmann, BS; Chrystal M. Paulos, PhD | Immune-stimulants and immune modulators | Adoptive immunotherapy;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 709 | Poster Presentation | Peptidyl IL-2/15Rβγc-restricted agonists, highly-attenuated and linked to anti-PD-1 antibodies to achieve selectivity and amplified potency in stimulating PD-1high lymphocytes | William J. Dower, PhD; Alice V. Bakker, BA; Steven E. Cwirla; Blake M. Williams, MS; Prarthana Joshi, ME; Praechompoo Pongtornpipat, MS; Michael C. Needels, PhD; Ronald W. Barrett, PhD | Immune-stimulants and immune modulators | Bispecifics;Checkpoint blockade;Cytokine;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 710 | Poster Presentation | Differences in the susceptibility of human small cell lung cancer variants to NK cell-mediated lysis can be overcome with the addition of N803 (IL-15 superagonist) | Kristen N. Fousek, PhD; Lucas A. Horn, PhD; Haiyan Qin; Bobby Reddy, MD; Lennie Sender, MD; Patrick Soon Shiong, MD; Jeffrey Schlom, PhD; Claudia M. Palena, PhD | Immune-stimulants and immune modulators | Cytokine;Immune adjuvant;NK/NKT cell;Tumor microenvironment |
| 711 | Poster Presentation | IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion | Thierry D. Giffon; Melanie Desbois; Dean Ng, Ph.D.; Poonam Yakkundi; Marigold Manlusoc; Miho Oyasu; Rodnie Rosete; Daniel Machado; Susan Calhoun; Tasnim Kothambawala; Avneesh Saini; Beatrice T. Wang, PhD; Maya Kotturi; Bruce A. Keyt, PhD; Angus M. Sinclair, PhD | Immune-stimulants and immune modulators | Antibody;Checkpoint blockade;Cytokine;NK/NKT cell;T cell |
| 712 | Poster Presentation | Preclinical characterization of GT-00A x IL15: A novel IL-15-based immunocytokine with unique tumor targeting properties | Anika Jaekel; Patrik Kehler; Timo Lischke; Christoph Goletz; Anke Flechner; Antje Danielczyk; Johanna Gellert | Immune-stimulants and immune modulators | Antibody;Bispecifics;Cytokine;NK/NKT cell;Solid tumors;Targeted therapy;Tumor microenvironment |
| 713 | Poster Presentation | Novel protease activatable linker with tumor targeting motifs enhances the retention of cytokine prodrug and active cytokine at disease site and demonstrates improved efficacy in preclinical model | Emma Langley; Chen Li; Jessica Zaid; Tani-Ann Lee; Deepak Yadav; Brian Grot; Jay Singh; Johnovan Kim | Immune-stimulants and immune modulators | Cytokine;Tumor microenvironment;Tumor stroma |
| 714 | Poster Presentation | Selective expansion of antigen-specific CD8 T cells with engineered Antigen Presenting Exosome | Tomoyoshi Yamano, phD; Xiabing Lyu; Rikinari Hanayama, M.D., phD | Immune-stimulants and immune modulators | Adoptive immunotherapy;Costimulation;Dendritic cell;T cell;Tumor antigens |
| 715 | Poster Presentation | WTX-330 is an IL-12 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models | Kristin Morris, PhD; Heather Brodkin; Daniel J. Hicklin, PhD; Nesreen Ismail; Christopher Nirschl, PhD; Andres Salmeron, PhD; Philipp Steiner, PhD; Zoe Steuert; Jenna Sullivan; William Winston | Immune-stimulants and immune modulators | Cytokine;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 716 | Poster Presentation | NL-201 induces inflammation in a 'cold' tumor microenvironment through upregulation of MHC-I, expansion of the TCR repertoire, and potent antitumor activity when combined with PD-1 inhibition | Christie Mortales, PhD; Benjamin Dutzar, BS; Jerry Chen, BS; Alex Chen, PhD; Justin Huard, BS; Luis Blancas-Mejia, PhD; Carl Walkey, PhD; Ryan Swanson, BS | Immune-stimulants and immune modulators | Checkpoint blockade;Cytokine;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs) |
| 717 | Poster Presentation | Selective activation of CD8+ T cells by a CD8-targeted IL-2 results in enhanced anti-tumor efficacy and safety | Kelly D. Moynihan, Ph.D.; Danielle Pappas; Terrence Park; Wei Chen, Ph.D.; Irene Ni; Paul Bessette, Ph.D.; Mike Chin; Ton N. Schumacher, PhD; Andy Yeung, Ph.D.; Ivana Djuretic, Ph.D. | Immune-stimulants and immune modulators | Cytokine;Solid tumors;T cell |
| 718 | Poster Presentation | WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models | Christopher Nirschl, PhD; Heather Brodkin, PhD; Daniel J. Hicklin, PhD; Nesreen Ismail; Kristin Morris, PhD; Andres Salmeron, PhD; Cindy Seidel-Dugan, PhD; Philipp Steiner, PhD; Zoe Steuert; Jenna Sullivan; William Winston, PhD | Immune-stimulants and immune modulators | Cytokine;Inflammation;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 719 | Poster Presentation | XTX301, a protein-engineered IL-12, exhibits tumor-selective activity in mice without peripheral toxicities and is well tolerated in non-human primates | Ekta Patel, PhD; Natalia Malkova; Sallyann Vu; Rebekah O'Donnell; Manoussa Fanny; Wilson Guzman; Parker Johnson; Megan McLaughlin; Oleg Yerov; Kurt Jenkins; Hanumantha Rao Madala; Caitlin O'Toole; Magali Pederzoli-Ribeil; Jia Chen; Benjamin Nicholson; Bill Avery; Huawei Qiu; Ronan O'Hagan; Jennifer O'Neil, PhD | Immune-stimulants and immune modulators | Cytokine;Solid tumors;T cell |
| 720 | Poster Presentation | CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies | Christie Zhang, PhD; Natasha Girgis, Ph.D.; Zohra Merazga, MSc; Steven Hatfield; Alex Histed, MSc; Fan Zhao, PhD; Raymond J. Moniz, PhD; Kristin Yeung; Fulvio Diaz; Jason Brown; Mark Haydock, B.S.; Luke Witt, B.S.; Wynona Bautista; John F. Ross, Ph.D.; Saso Cemerski, PhD; Anish Suri, PhD; Kenneth J. Pienta, MD; Matteo Levisetti; Steve N. Quayle, PhD | Immune-stimulants and immune modulators | Bispecifics;Cytokine;T cell;Tumor antigens |
| 721 | Poster Presentation | Intratumoral immunotherapy with aluminum hydroxide-tethered IL-12 induces potent local and systemic immunity with minimal toxicity | Michael M. Schmidt, PhD; Gregory Papastoitsis; Howard L. Kaufman, MD; Darrell J. Irvine, Ph.D.; K. D. Wittrup | Immune-stimulants and immune modulators | Costimulation;Cytokine;Immune adjuvant;Immune toxicity;Solid tumors;Tumor microenvironment |
| 722 | Poster Presentation | INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities | Florian J. Sulzmaier, PhD; Heather Kinkead, PhD; Anya Polovina; Nadja Kern; Angelica Sanabria; Chelsie Macedo; Abrahim Hussain; Sae Jeong Ahn; Rajay Pandit; William Crago; John C. Timmer, PhD; Analeah B. Heidt, PhD; Brendan P. Eckelman, PhD | Immune-stimulants and immune modulators | Antibody;Bispecifics;Cytokine;NK/NKT cell;Targeted therapy |
| 723 | Poster Presentation | WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models | Ethika Tyagi, PhD; Heather Brodkin, PhD; Josue Canales; Dan Hicklin; Nesreen Ismail; Kristin Morris, PhD; Christopher Nirschl, PhD; Andres Salmeron, PhD; Cindy Seidel-Dugan, PhD; Philipp Steiner, PhD; Zoe Steuert; Jenna Sullivan; William Winston, PhD | Immune-stimulants and immune modulators | Cytokine;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 724 | Poster Presentation | Evaluation of an Anti-human IL-1β Antibody in Monosodium Urate Crystals-Induced Peritonitis Model in hIL-1β HuGEMM™ Mice | Xiaoyu An, MS; Kaixia Lian; Jia Zheng; Fei Jian; Henry Q. Li; Tao Yang, PhD | Immune-stimulants and immune modulators | Autoimmunity;Cytokine;Inflammation |
| 725 | Poster Presentation | Immunomodulation by targeting PDL-1 in colon cancer using nuclear receptor 4A1 (NR4A1) antagonists | Maen Abdelrahim, MD, PhD; Kumaravel Mohankumar, Ph.D.; Keshav Karki, PhD; Stephen Safe | Immune-stimulants and immune modulators | Gene expression;Immune adjuvant;Solid tumors;Targeted therapy;Tumor antigens;Tumor microenvironment |
| 726 | Poster Presentation | Tumor Treating Fields (TTFields) induce an altered polarization program in M1/M2 macrophages | Yiftah Barsheshet, PhD; Boris Brant; Tali Voloshin; Alexandra Volodin; Lilach Koren; Anat Klein-Goldberg; Efrat Zemer-Tov; Rom Paz; Moshe Giladi, PhD; Uri Weinberg, MD PhD; Yoram Palti | Immune-stimulants and immune modulators | Antigen presenting cells;Immune adjuvant;Inflammation;Monocyte/Macrophage |
| 727 | Poster Presentation | Resistance to enzalutamide and abiraterone drives tumor phenotypic plasticity and resistance to immune-mediated cytotoxicity | Madeline Dahut, BS; Kristen N. Fousek, PhD; Lucas A. Horn, PhD; Haiyan Qin; Jeffrey Schlom, PhD; Claudia M. Palena, PhD | Immune-stimulants and immune modulators | NK/NKT cell;Tumor evasion;Tumor microenvironment |
| 729 | Poster Presentation | Immunologic tumor cell intrinsic effects of standard of care therapies for ovarian cancer | Nicole E. James, PhD; Melih A. Ozsoy; Payton De La Cruz; Morgan Woodman; Jennifer Ribeiro | Immune-stimulants and immune modulators | Chemotherapy;Cytokine;Solid tumors |
| 730 | Poster Presentation | Hypoxia reduction in tandem with anti-angiogenic therapy remodels the PDAC microenvironment and potentiates CD40 agonist therapy | Arthur J. Liu, BS; Michael A. Curran, PhD | Immune-stimulants and immune modulators | Angiogenesis;Checkpoint blockade;Immune suppression;Myeloid cells;Solid tumors;T cell;Tumor microenvironment;Tumor stroma |
| 731 | Poster Presentation | Concurrent immunotherapy and dipeptidyl peptidase-4 inhibition among patients with solid tumors | Kayla W. Miranda, MD; Matthew D. Tucker, MD; Yu-Wei Chen, MD; Kathryn E. Beckermann, MD, PhD; Brian I. Rini, MD | Immune-stimulants and immune modulators | Checkpoint blockade;Clinical study;Immune toxicity;Solid tumors;Tumor microenvironment |
| 732 | Poster Presentation | A novel nuclear receptor 4A1 (NR4A1) antagonists attenuates T-cell exhaustion in colorectal cancer | Kumaravel Mohankumar, Ph.D.; Gus Wright, Ph.D.; Subhashree Kumaravel; Rupesh Shrestha; Maen Abdelrahim, MD, PhD; Robert S. Chapkin, Ph.D; Stephen Safe | Immune-stimulants and immune modulators | Checkpoint blockade;Gene expression;Solid tumors;T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 733 | Poster Presentation | Immunological mechanisms of resistance to CDK4/CDK6 inhibitors in breast cancer | Giulia Petroni, PhD; Kenneth Gouin; Aitziber Buqué Martinez, PhD; Simon Knott; Silvia C. Formenti, MD; Lorenzo Galluzzi, PhD | Immune-stimulants and immune modulators | Immune contexture;Monocyte/Macrophage;Radiotherapy;Regulatory T cell (Treg cell);T cell;Tumor microenvironment |
| 734 | Poster Presentation | BET inhibitors synergize with anti-PD1 by rescuing TCF1+ progenitor exhausted T cells in Acute Myeloid Leukemia | Kyle A. Romine; Hyun-Jun Cho; Yoko Kosaka, PhD; Kaelan Byrd; Jesse Coy; Patrick Flynn; Matthew Newman; Christopher Loo; Evan F. Lind, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Epigenetics;Leukemia/Lymphoma |
| 735 | Poster Presentation | Identification of a small molecule that prevents T cell Exhaustion using machine learning algorithms paired with high-resolution single cell RNAseq | Isabelle Le Mercier, PhD; Sunny Sun; Dongmei Xiao; Laura Isacco; Daniel Treacy; Emilie Artru; Scott Steelman; John Bradley; Alex Wolf; Morag Stewart; Effie Tozzo | Immune-stimulants and immune modulators | Immune suppression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 736 | Poster Presentation | Treatment with decitabine (DAC) induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer | Nassiba Taib, Mater's degree; Maysaloun Merhi; Varghese Inchakalody; Sarra Mestiri; Afsheen Raza, PhD; Shahab Uddin; Cristina Maccalli; Mohammed Ussama AlHomsi; Said Dermime | Immune-stimulants and immune modulators | Chemotherapy;Epigenetics;Neoantigens |
| 737 | Poster Presentation | Inhibition of P21-activated kinase 4 (PAK4) reverts immune exclusion and restores anti-tumor immunity in the tumor microenvironment | Yu 'Jerry' Zhou; Gina Chu; Eleanore Hendrickson; Johnni Gullo-Brown; Brandy Chavez; Indrawan McAlpine; Eugene Rui; Shawn Doran; Sergei Timofeevski; Jonathan Heyen; Jennifer Kinong; Szu-Yu Tang; Jon Oyer; Vinayak Rayannavar; Andrew Nager; Keith Ching; Stephanie Shi; Rajarshi Bhadra; Christopher Dillon; Murali Gururajan | Immune-stimulants and immune modulators | Immune suppression;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 738 | Poster Presentation | Intratumoral administration of alum-tethered engineered inflammatory cytokines safely elicits potent local and systemic immunity | Yash Agarwal, B.Sc.; K. D. Wittrup; Darrell J. Irvine, Ph.D. | Immune-stimulants and immune modulators | Checkpoint blockade;Cytokine;Immune adjuvant;Solid tumors |
| 739 | Poster Presentation | Intratumor childhood vaccine-specific CD4+ T cell recall helps antitumor CD8 T cells | Michael C. Brown, PhD; Zachary P. McKay; Yuanfan Yang, MD; Darell D. Bigner, MD, PhD; Smita Nair, PhD; Matthias Gromeier, MD | Immune-stimulants and immune modulators | Antigen presenting cells;Costimulation;Dendritic cell;Immune adjuvant;Immune contexture;Inflammation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 740 | Poster Presentation | Radiotherapy-activated NBTXR3 nanoparticles Increase CD8+ T cell infiltration and diversity in tumors, and modulate the immunopeptidome of cancer cells | Audrey Darmon, BS; Ping Zhang, PhD; Jordan Da silva; Sebastien Paris | Immune-stimulants and immune modulators | Biomarkers;Radiotherapy;Surfaceome;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 741 | Poster Presentation | Expression of galectin-3 inhibitors from a self-replicating RNA vector as treatment for pediatric osteasarcoma | Guillermo Herrador Cañete, Jr., MSc; Marta Zalacain, PhD; Sara Labiano, PhD; Javier Martinez, MSc; Cristian Smerdou, PhD; Marta M. Alonso | Immune-stimulants and immune modulators | Gene expression;Immune suppression;Pediatric tumors;Solid tumors;Tumor microenvironment |
| 742 | Poster Presentation | Multi-armed myxoma virus induces potent anti-tumor responses in vitro and in vivo | Wazir Abdullahi, PhD; Lina S. Franco, PhD; Christopher Fraser, PhD; Heather Hrach, PhD; Nicole Grigaitis; Mario Abrantes; Zachary Tacner; Ana L. de Matos, PhD; Leslie L. Sharp, PhD; LESLIE L. SHARP, PhD | Immune-stimulants and immune modulators | Costimulation;Cytokine;NK/NKT cell;Solid tumors;T cell;Tumor stroma |
| 743 | Poster Presentation | Resistance to oncolytic vaccinia can be reversed by targeting regulatory T cells with vaccinia-directed delivery of a TGFβ inhibitor | Kristin DePeaux, BS; Dayana Rivadeneira, PhD; McLane Watson, BS; Andrew P. Hinck; Stephen Thorne; Greg M. Delgoffe, PhD | Immune-stimulants and immune modulators | Immune adjuvant;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 744 | Poster Presentation | Multi-armed myxoma virus has therapeutic potential for treatment of multiple myeloma | Lina S. Franco, PhD; Christopher Fraser, PhD; Lino E. Torres-Dominguez, PhD; Nicole Grigaitis; Jack St. Peter; Mario Abrantes; Zachary Tacner; Heather Hrach, PhD; Ana L. de Matos, PhD; Leslie L. Sharp, PhD | Immune-stimulants and immune modulators | Costimulation;Cytokine;Leukemia/Lymphoma;NK/NKT cell;T cell |
| 745 | Poster Presentation | Oncolytic adenovirus expressing 4-1BBL demonstrates a significant increase of survival in Diffuse Midline Glioma models | Virginia Laspidea; Sara Labiano, MSc; Iker Ausejo-Mauleon, MSc; Daniel de la Nava; Marc García-Moure; Javier Marco-Sanz; Juan Fueyo; Candelaria Gomez-Manzano; Ana Patiño-García; Marta M. Alonso | Immune-stimulants and immune modulators | Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 746 | Poster Presentation | Vectorized Treg-depleting anti-CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors | Monika Semmrich, PhD; Jean-Baptiste j. Marchand, PhD; Matilda Rehn, PhD; Laetitia Fend, PhD; Christelle Remy-Ziller, Engineer; Petra Holmkvist, PhD; Nathalie Silvestre, PhD; Carolin Svensson; Patricia Kleinpeter, MSc; Jules Deforges; Fred Junghus; Linda Martensson; Johann Foloppe, PhD; Ingrid Teige, M.Sc, PhD; Eric Quemeneur, PharmD, PhD; Bjorn Frendeus, PhD | Immune-stimulants and immune modulators | Antibody;Checkpoint blockade;Regulatory T cell (Treg cell);Solid tumors |
| 747 | Poster Presentation | CodaLytic™, a novel codon-pair deoptimized influenza virus creates an immune-stimulatory tumor microenvironment leading to monotherapy efficacy in a preclinical model of breast cancer | Marcin Stawowczyk, PhD; Katie Pfeffer; Juliana Tafrova, PhD; Charles B. Stauft, PhD; Anna Kushnir, PhD; Sybil A. Tasker, MD, MPH, FIDSA; Steffen Mueller, PhD; J Robert Coleman, PhD, MBA; Johanna K. Kaufmann, PhD | Immune-stimulants and immune modulators | B cell;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 748 | Oral Presentation | Targeting vasoactive intestinal peptide receptor signaling in pancreatic ductal adenocarcinoma for enhanced anti-tumor response to checkpoint blockade | Sruthi Ravindranathan, PhD, MS; Tenzin Passang Fnu; Jian Ming Li; Rohan Dhamsania; Michael B. Ware, PhD; Mohammad Y. Zaidi; Shuhua Wang; Jingru Zhu; Maria Cardenas; Yuan Liu, PhD; Sanjeev Gumber; Brian Robinson; Anish Majumdar,; Shanmuganathan Chandrakasan; Haydn T. Kissick, PhD; Alan B. Frey; Susan N. Thomas; Bassel El-Rayes, MD; Gregory B. Lesinski, PhD; Edmund K. Waller, MD/PHD | Immune-stimulants and immune modulators | Solid tumors;Targeted therapy |
| 749 | Poster Presentation | A novel translational mouse model for assessment of human STING-targeting therapies | Fabiane Sônego; Fabiane Sônego, PhD; Gaëlle Martin; Audrey Beringer; Chloé Beuraud; Angela Pappalardo; Yacine Cherifi; Patricia Isnard-Petit; Kader Thiam | Immune-stimulants and immune modulators | Inflammation;Targeted therapy |
| 750 | Poster Presentation | AK119, A CD73 Targeting Antibody with Dual Mechanism of Action | Zhaoliang Huang, BSc; Xinghua Pang, BSc; Tingting Zhong, MS; Chunshan Jin; na chen, MD; Xinrong He; Dennis Xia, Ph.D; Xiaoping Jin, PhD; Zhongmin Wang; Xu Xia; Baiyong Li, Ph.D | Immune-stimulants and immune modulators | Antibody;B cell;COVID and Immunotherapy;Immune suppression;T cell |
| 751 | Poster Presentation | Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb | Karin Hagerbrand, PhD; Mattias Levin; Laura Von Schantz, -; Laura Varas, PhD; Anna Säll; Adnan Deronic, PhD; Anette Sundstedt; Lill Ljung; Karin Barchan; Doreen Werchau, BS; Anna Rosén; Barnabas Nyesiga; Eva Lindqvist; Mia Thagesson; Peter Ellmark, PhD | Immune-stimulants and immune modulators | Antibody;Bispecifics;Costimulation;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor antigens;Tumor microenvironment |
| 752 | Poster Presentation | Novel, orally administered HPK1 inhibitors demonstrate anti-tumor efficacy and enhanced immune response | Stefan Chmielewski, PhD; Maciej Kujawa; Eliza Zimolag; Michal Galezowski; Andrzej Gondela; Pawel Guzik; Agata Dudek; Joanna Szeremeta-Spisak; Marta Bugaj; Iana Levenets; Marcin Nowogrodzki; Marianna Girardi; Anna Zagorska; Przemyslaw Wyrebek; Magdalena Zastawna; Agnieszka Gibas; Sylwia Sudol; Oleksandr Levenets; Mateusz Swirski; Sujit Sasmal; Adam Radzimierski; Marta Sowinska; Paulina Niedziejko; Karol Zuchowicz; Martin Swarbrick; Karolina Gluza; Patryk Kret; Mateusz Ogorek; Dominika Stanko; Kinga Michalik; Agnieszka Piatek; Katarzyna Banaszak; Adrian Podkowa; Aniela Golas; Peter Littlewood; Krzysztof Brzozka; Stefan Chielewski | Immune-stimulants and immune modulators | Cytokine;Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs) |
| 753 | Poster Presentation | InhibigenTM administration promotes aberrant T cell responses in cancer but may be beneficial for amelioration of autoimmune disease | Victoria L. DeVault, PhD; Hanna Starobinets, PhD; Julie N. Arnold; Stephanie Rinaldi; Charley Hubbard, PhD; Osaruese Odeh; Cindy Nguyen; Laura Apolloni; Dimitry Lineker; Jessica B. Flechtner, PhD; Hubert Lam, PhD | Immune-stimulants and immune modulators | Adoptive immunotherapy;Checkpoint blockade;Immune suppression;Neoantigens;T cell;Targeted therapy;Tumor antigens;Vaccine |
| 754 | Poster Presentation | TIGIT-PVR is a key immune checkpoint and therapeutic target in HPV-positive head and neck squamous cell carcinomas | Xiuning Le, MD, PhD; Minghao Dang; Venkatesh L. Hegde, PhD; Bo Jiang; Ravaen Slay; Weihong Xiao, MD; Keiko Akagi, PhD; Joseph Fresquez; Kathrina L. Marcelo, PhD; Qianyun Luo; Pragya Sinha; Ananta V. Yanamandra; Diana Bell, MD; Michelle Williams, MD; Edwin Parra Cuentas, PhD; Ryan Goepfert, MD; Stephen H. Lai, MD, PhD; Neil Gross, MD; Amit Agrawal, MD; Alexandre Reuben, PhD; Jeffrey Myers, MD, PhD; Michael A. Curran, PhD; Jagannadha Sastry, PhD; Linghua Wang, PhD; Maura L. Gillison, MD, PhD | Immune-stimulants and immune modulators | Biomarkers;Checkpoint blockade;Coinhibition;Immune suppression;Solid tumors;Tumor microenvironment |
| 755 | Poster Presentation | Pharmacologic tumor PD-L1 depletion reduces Chk2 content and sensitizes tumors to small molecule Chk1 DNA damage repair inhibitors | Clare E. Murray; Anand V. Kornepati; Alvaro S. Padron; Myrna G. Garcia, BS; Haiyan HB. Bai, PhD; Yilun Deng, PhD; Tyler J. Curiel, MD | Immune-stimulants and immune modulators | Biomarkers;Checkpoint blockade;Chemotherapy;Coinhibition;Immune monitoring;Solid tumors;Targeted therapy;Tumor antigens;Tumor evasion;Tumor microenvironment |
| 756 | Poster Presentation | Identifying the role of B7-H4 as a suppressor of tumor infiltrating lymphocytes and a target for immunotherapy in breast cancer | Elizabeth Wescott, BS; Paula I. Gonzalez-Ericcson, MD; Violeta I. Sanchez, BS; Melinda Sanders, MD; Justin M. Balko, PharmD, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Immune suppression;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 757 | Poster Presentation | M9657, a novel tumor-targeted conditional anti-CD137 agonist displays MSLN-dependent anti-tumor immunity | Chunxiao Xu, PhD; Brain Rabinovich; Amit Deshpande; Xueyuan Zhou; Frederic Christian Pipp; Rene Schweickhardt; Lindsay Webb; Sireesha Yalavarthi; Clotilde Bourin; Payel Ghatak; Barroq Safi; Francisca Wollerton; Neil Brewis; Jose Munoz-Olaya; Natalya Belousova; Marat Alimzhanov; Martina Hubensack; Joern-Peter Halle; Andree Blaukat; Jacques Moisan | Immune-stimulants and immune modulators | Costimulation;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 758 | Poster Presentation | High-potency synthetic STING agonists rewire the myeloid stroma in the tumour microenvironment to amplify immune checkpoint blockade efficacy in refractory pancreatic ductal adenocarcinoma. | Akash R. Boda, MS; Casey R. Ager, PhD; Kimal Rajapakshe, PhD; Spencer T. Lea, BA; Maria Emilia Di Francesco, PhD; Philip Jones, PhD; Michael A. Curran, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Dendritic cell;Immune suppression;MDSC;Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 759 | Poster Presentation | Single-Cell Proteogenomics (Cite-seq) analysis of cGAS-STING pathway activation alone and in combination with nivolumab using a patient-derived 3D ex vivo tumoroid platform | Brittany Bunch, PhD; Autumn Joerger, PA; Nino Mtchedlidze; Olivia Hoff; Kelly Guzman; Jared C. Ehrhart, PhD; Soner Altiok, MD, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Gene expression;RNA;Solid tumors;Tumor microenvironment;Tumor stroma |
| 760 | Poster Presentation | In vivo demethylation-mediated reversal of tumor cell-intrinsic cGAS silencing improves the efficacy of STING agonist therapy | Rana Falahat, PhD; Patricio Perez-Villarroel; Anders Berglund, PhD; Shari A. Pilon-Thomas, PhD; Glen N. Barber, PhD; James J. Mule, PhD | Immune-stimulants and immune modulators | Chemokine;Epigenetics;Immune adjuvant;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 761 | Poster Presentation | exoSTING demonstrates potent anti-tumor activity in a mouse model of leptomeningeal disease | Xudong Feng, PhD; John Lin, PhD; Su Chul Jang, PhD; Sevda Lule, PhD; Paloma Sanchez-Jauregui; Katherine Kirwin; Tong Zi; Samuel Kasera; Silvia Siso, PhD; Kelvin Zhang, PhD; Shil Patel, PhD; Sriram Sathyanarayanan, PhD; Kyriakos Economides, PhD; Wendy Broom, PhD | Immune-stimulants and immune modulators | Extracellular vesicles/exosomes;Solid tumors |
| 762 | Poster Presentation | STING agonism combined with arginase, NOS2, and PTGES/COX2 inhibitors for improved anti-tumor immunotherapeutic benefit | Jessica Filderman, BS; Manoj Chelvanambi, BS; Walter J. Storkus, PhD | Immune-stimulants and immune modulators | Angiogenesis;Inflammation;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 763 | Poster Presentation | Intratumoral delivery of high potency STING agonists modulates the immunosuppressive myeloid compartment and induces curative responses in checkpoint-refractory Glioblastoma models | Spencer T. Lea, BA; Chao-Hsien Chen, MD, PhD; Genevieve P. Hartley, PhD; Rodney Cheng-En Hsieh, MD; Michael A. Curran, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Immune adjuvant;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 764 | Poster Presentation | Characterization of RVU-27065 a novel small-molecule STING agonist suitable for systemic administration | Maciej K. Rogacki, MSc; Stefan Chmielewski, PhD; Magdalena Zawadzka; Aniela Golas; Aleksandra Poczkaj; Katarzyna Dziedzic; Kamil Kus; Magnus Widegren; Jolanta Mazurek; Miroslawa Gladysz; Justyna Jablonska; Izabela Strojny; Grzegorz Cwiertnia; Lukasz Dudek; Marcin Les; Urszula Glowniak-Kwitek; Nilesh Gaud; Arkadiusz Bialas; Kinga Michalik; Raghuram Tangirala; Peter Littlewood; Krzysztof Brzózka | Immune-stimulants and immune modulators | Antigen presenting cells;Cytokine;Inflammation |
| 765 | Poster Presentation | The first-in-class small molecule TREX1 inhibitor CPI-381 demonstrates type I IFN induction and sensitization of tumors to immune checkpoint blockade | Costa Salojin, MD, PhD; Costa Salojin; Anna S. Gardberg; Valerie Vivat; Lei Cui; Jeffrey Lauer; Nico R. Cantone; Jacob I. Stuckey; Florence Poy; Ingrid Almeciga; Richard T. Cummings; Jonathan Wilson; Julian R. Levell; Jennifer L. Rocnik; Patrick Trojer | Immune-stimulants and immune modulators | Checkpoint blockade;Cytokine;Dendritic cell;Immune adjuvant;Solid tumors;Tumor microenvironment |
| 766 | Poster Presentation | Toward safe, systemic delivery of synthetic TLR7/8 agonists using Bottlebrush Prodrugs (BPDs) | Sachin H. Bhagchandani, M.S.; Lauren Milling, Ph.D.; Bin Liu, Ph.D.; Timothy Fessenden, Ph.D.; Stefani Spranger, PhD; Darrell J. Irvine, Ph.D.; Jeremiah A. Johnson, Ph.D. | Immune-stimulants and immune modulators | Antigen presenting cells;Checkpoint blockade;Immune adjuvant;Immune toxicity;TLR;Tumor microenvironment |
| 767 | Poster Presentation | Activation of CD8+ T cells in the presence of multiple TLR agonists affects the expression of T-cell checkpoint receptors via IL-12 and type-1 interferon | Donghwan Jeon, MS; Douglas G. McNeel, MD, PhD | Immune-stimulants and immune modulators | Immune adjuvant;T cell;TLR;Vaccine |
| 768 | Poster Presentation | Systemic delivery of a tumor-targeted TLR9 agonist conjugate transforms the tumor immune landscape and induces tumor regression in mice | Caitlyn Miller, PhD Candidate; Idit Sagiv-Barfi, PhD; Patrick Neuhoefer, PhD; Debra K. Czerwinski, BS; Steven Artandi, MD; Carolyn Bertozzi, PhD; Ronald Levy, MD; Jennifer Cochran, PhD | Immune-stimulants and immune modulators | Immune adjuvant;Immune suppression;Inflammation;MDSC;Solid tumors;T cell;Targeted therapy;TLR;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 769 | Poster Presentation | A Single Dose of Intratumoral TransCon™ TLR7/8 Agonist Monotherapy Promoted Sustained Activation of Antigen Presenting Cells Resulting in CD4+ and CD8+ T cell Activation and Tumor Growth Inhibition | Luis Zuniga, PhD; Karan Uppal, PhD; Kathy Bang; Enping Hong, PhD; Simran Sabharwal, PhD; Yuchi Lee, PhD; Solomon Martinez; David Rosen, PhD; Amer M. Mirza, PhD; Juha Punnonen, MD, PhD; Luis A. Zuniga, PhD | Immune-stimulants and immune modulators | Antigen presenting cells;Inflammation;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;TLR;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 770 | Poster Presentation | Personalized synthetic polyepitope DNA cancer vaccines encoding a novel pyroptotic adjuvant to generate effective anti-tumor T cell immunity | Jeroen J. Van Bergen, PhD; Tsolere Arakelian, PhD; Kedar Moharana, PhD; Bram Teunisse; Iris Zoutendijk; Marcel Camps; Ramon Arens; Ferry Ossendorp, PhD; Gerben Zondag, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Cytokine;Immune adjuvant;Inflammation;Neoantigens;T cell;Vaccine |
| 771 | Poster Presentation | Novel lipid nanoparticle vaccine platform for efficient delivery of high- and low-affinity epitopes | Unnur Jóna Björgvinsdóttir; Laura Stentoft Carstensen; Anna Colliander; Ditte Elisabeth Jæhger; Gael Clergeaud Veiga; Hólmfríður Rósa Halldórsdóttir; Matilde Smærup Jørgensen; Esben Christensen; Sara Vangsgaard; Aristeidis Koukos; Martin Bak; Paul Kempen; Thomas Lars Andresen; Unnur Jóna Ms. Björgvinsdóttir, MSc | Immune-stimulants and immune modulators | Adoptive immunotherapy;Antigen presenting cells;Immune adjuvant;T cell;TLR;Vaccine |
| 772 | Poster Presentation | MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination | Mathieu Gigoux, PhD; Roberta Zappasodi, PhD; Joseph J. Park; Cansu Cimen Bozkus; Levi M. Mangarin, BS; David Redmond; Svena Verma, BS; Sara Schad, BS; Mariam M. George; Divya Venkatesh; Arnab Ghosh, MD, PhD; Zaki Molvi, BS; Baransel Kamaz; Anna Marneth; William Duke; Matthew J. Leventhal; Max Jan; Vincent Ho; Gabriela S. Hobbs; Trine A. Knudsen; Vibe Skov; Lasse Kjær; Thomas S. Larsen; Dennis L. Hansen; R. C. Lindsley; Hans Hasselbalch; Jacob H. Grauslund; Mads H. Andersen, Professor, PhD, dr.techn; Morten O. Holmstrom; Timothy A. Chan, MD, PhD; Raajit Rampal; Omar Abdel-Wahab, M.D.; Nina Bhardwaj, MD, PhD; Jedd D. Wolchok, MD/PhD; Ann Mullally, M.D.; Taha Merghoub, PhD | Immune-stimulants and immune modulators | Neoantigens;Tumor antigens;Tumor evasion;Vaccine |
| 773 | Poster Presentation | A novel cancer immunotherapy; vaccination against tumor vascular extracellular vimentin | Elisabeth J. Huijbers, PhD; Karlijn van Loon; Judy R. van Beijnum; Arjan W. Griffioen | Immune-stimulants and immune modulators | Angiogenesis;Solid tumors;Vaccine |
| 774 | Poster Presentation | An induced pluripotent stem cell (iPSC) vaccine is highly immunogenic and reduces lung metastases in a mouse model of melanoma | Matthias Hundt, MD; Peter F. Bove, PhD; Ivan Hernandez, MS; Michelle Li, MS; Lucia Beviglia, PhD; Pratima Kundu, PhD; Babacar C. Ndoye, BS; Nigel G. Kooreman, MD; Stephen D. Wolpe, PhD; Lynne A. Bui, MD | Immune-stimulants and immune modulators | Antibody;B cell;Checkpoint blockade;Immune adjuvant;Solid tumors;T cell;TLR;Vaccine |
| 775 | Poster Presentation | An induced pluripotent stem cell (iPSC) vaccine decreases tumor growth and improves survival in a therapeutic mouse model of colon cancer | Matthias Hundt, MD; Michelle Li, MS; Hui Huang, MD; Carlos A. Obejero-Paz, MD; Peter F. Bove, PhD; Ivan Hernandez, MS; Pratima Kundu, PhD; Nigel G. Kooreman, MD; Stephen D. Wolpe, PhD; Lynne A. Bui, MD | Immune-stimulants and immune modulators | Antibody;B cell;Checkpoint blockade;Immune adjuvant;Solid tumors;T cell;TLR;Vaccine |
| 776 | Poster Presentation | The anti-tumor activity of HER-2/neu ICD therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in Her2-expressed gastric cancer xenograft model | Gyeong Seok Jo; Eunkyo Joung, MD; Jung Hyu Shin; Hye Lim Lee; Jinback Lim; Yoonyi Kim; Hyo-Hyun Park; Hunwoo Shin; Hun JH. Jung, MD./PhD. | Immune-stimulants and immune modulators | Carcinogenesis;Cytokine;Immune monitoring;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 777 | Poster Presentation | Personalized DNA vaccine in combination with plasmid encoded IL-12 for the treatment of a patient with anaplastic astrocytoma | Tanner M. Johanns, MD, PhD; ALFREDO PERALES-PUCHALT, MD, PhD; Sarah Rochestie; Neil Cooch; Joann Peters; Gavin P. Dunn, MD, PhD; Niranjan Y. Sardesai | Immune-stimulants and immune modulators | Immune monitoring;T cell;Tumor antigens;Vaccine |
| 778 | Poster Presentation | Modulating tumor microenvironment with arginase-1 specific T cells | Evelina Martinenaite, PhD; Mia Aaboe Jørgensen; Rasmus Erik Johansson Mortensen; Shamaila Munir Ahmad; Stine Emilie Weis-Banke; Morten Orebo Holmström; Ayako Wakatsuki Pedersen; Özcan Met; Inge M. Svane, Professor, MD, PhD; Mads Hald Andersen | Immune-stimulants and immune modulators | Immune suppression;Inflammation;Monocyte/Macrophage;Myeloid cells;T cell;Targeted therapy;Tumor microenvironment;Vaccine |
| 779 | Poster Presentation | Inhibiting Type-I Interferon signaling promotes memory T-cell formation following immunization with Listeria anti-cancer vaccines | Zachary T. Morrow, BS; John-Demian Sauer, PhD, BS | Immune-stimulants and immune modulators | Antigen presenting cells;Dendritic cell;Granulocyte;Immune monitoring;Inflammation;Microbiome;Monocyte/Macrophage;T cell lineages;TLR;Vaccine |
Presented By:
